MedTrace Logo

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

NCT07619235 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-06-01

No results posted yet for this study

Summary

This is a single-arm, multicenter clinical study designed to evaluate the efficacy and safety of Iparomlimab and Toripalimab (QL1706) in combination with bevacizumab and chemotherapy as first-line treatment for patients with advanced biliary tract cancer

Conditions

  • Biliary Tract Cancer (BTC)

Interventions

DRUG

Iparomlimab and Toripalimab

Iparomlimab and Toripalimab (QL1706): 7.5 mg/kg, intravenous (IV), once every 3 weeks (Q3W), Day 1.

DRUG

Bevacizumab

Bevacizumab: 7.5 mg/kg, IV, Q3W, Day 1.

DRUG

Gemcitabine (1000 mg/m2)

Gemcitabine: 1000 mg/m², IV, Q3W, Days 1 and 8

DRUG

Cisplatin

Cisplatin: 25 mg/m², IV, Q3W, Days 1 and 8

Sponsors & Collaborators

  • Xianglin Yuan

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2028-07-01
Completion
2028-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07619235 on ClinicalTrials.gov